title: Differential ezrin and phosphorylated ezrin expression profiles between pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm, and invasive ductal carcinoma of the pancreas.
abstract: Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) are important premalignant lesions of pancreatic cancer. Ezrin is a member of the ezrin, radixin, and moesin protein family and acts as a cross-linker between the plasma membrane and the actin cytoskeleton. We investigated the roles of ezrin during carcinogenesis in IPMN and invasive ductal carcinoma and examined whether ezrin was a prognostic factor. We examined ezrin and phosphorylated ezrin (p-ezrin) expression in 131 IPMNs, 47 PanINs, and 59 invasive ductal carcinomas by immunohistochemical staining. Ezrin and p-ezrin (tyr354) expressions were significantly higher in IPMN with an associated invasive carcinoma, compared with those in IPMN with high-grade dysplasia (P = .03 and P = .0007, respectively). In all grades of PanINs, ezrin and p-ezrin (tyr353) were highly expressed. In patients with invasive ductal carcinoma, the presence of PanIN-2 or PanIN-3 was significantly correlated with positive ezrin and p-ezrin (tyr353) expression of the invasive ductal carcinoma component (P = .01 and P = .0004). The negative p-ezrin (tyr353) expression group of invasive ductal carcinoma showed a significantly worse prognosis than did the positive p-ezrin (tyr353) expression group by survival analysis (P = .04) and was a statistically significant adverse prognostic factor by both univariate and multivariate analyses (P = .048 and P = .015). Ezrin phosphorylation sites differ between the developments of IPMN and PanIN. Although p-ezrin (tyr354) expression in IPMNs is associated with tumor invasion, p-ezrin (tyr353) expression in invasive ductal carcinoma plays an important role not in tumor invasion and metastasis but in the early development of PanINs.
authors: Department of Anatomic Pathology, Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, Fukuoka 812-8582, Japan.
authors: Yasunori
authors: Y
authors: Oda
authors: Shinichi
authors: S
authors: Aishima
authors: Katsuya
authors: K
authors: Morimatsu
authors: Akifumi
authors: A
authors: Hayashi
authors: Koji
authors: K
authors: Shindo
authors: Minoru
authors: M
authors: Fujino
authors: Yusuke
authors: Y
authors: Mizuuchi
authors: Masami
authors: M
authors: Hattori
authors: Masao
authors: M
authors: Tanaka
authors: Yoshinao
authors: Y
authors: Oda
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D014408:Biomarkers, Tumor / Q000032:analysis; D002278:Carcinoma in Situ / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D002291:Carcinoma, Papillary / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D003598:Cytoskeletal Proteins / Q000032:analysis / Q000096:biosynthesis*; D018450:Disease Progression; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010766:Phosphorylation; D000099149:Ezrin
chemical_list: D014408:Biomarkers, Tumor; D003598:Cytoskeletal Proteins; D000099149:Ezrin
keywords: Ezrin; Pancreas; Prognosis